S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Trading S.A. Ares Sells 4,584 Shares of Precigen, Inc. (NASDAQ:PGEN) Stock

Last updated on Tuesday, September 14, 2021 | 2021 MarketBeat

Precigen, Inc. (NASDAQ:PGEN) major shareholder Trading S.A. Ares sold 4,584 shares of Precigen stock in a transaction dated Friday, September 10th. The stock was sold at an average price of $6.29, for a total value of $28,833.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Trading S.A. Ares also recently made the following trade(s):

  • On Wednesday, September 8th, Trading S.A. Ares sold 2,400 shares of Precigen stock. The shares were sold at an average price of $6.23, for a total value of $14,952.00.
  • On Friday, September 3rd, Trading S.A. Ares sold 29,065 shares of Precigen stock. The shares were sold at an average price of $6.42, for a total value of $186,597.30.
  • On Wednesday, September 1st, Trading S.A. Ares sold 254,932 shares of Precigen stock. The shares were sold at an average price of $6.21, for a total value of $1,583,127.72.
  • On Monday, August 30th, Trading S.A. Ares sold 30,000 shares of Precigen stock. The stock was sold at an average price of $5.97, for a total value of $179,100.00.
  • On Thursday, August 26th, Trading S.A. Ares sold 111,229 shares of Precigen stock. The stock was sold at an average price of $5.95, for a total value of $661,812.55.
  • On Tuesday, August 24th, Trading S.A. Ares sold 33,407 shares of Precigen stock. The stock was sold at an average price of $5.86, for a total value of $195,765.02.
  • On Monday, August 16th, Trading S.A. Ares sold 6,313 shares of Precigen stock. The stock was sold at an average price of $6.13, for a total value of $38,698.69.
  • On Friday, August 13th, Trading S.A. Ares sold 52,031 shares of Precigen stock. The stock was sold at an average price of $6.20, for a total value of $322,592.20.
  • On Wednesday, August 11th, Trading S.A. Ares sold 257,800 shares of Precigen stock. The stock was sold at an average price of $6.11, for a total value of $1,575,158.00.
  • On Monday, August 9th, Trading S.A. Ares sold 56,528 shares of Precigen stock. The stock was sold at an average price of $5.59, for a total value of $315,991.52.

PGEN stock traded down $0.40 during midday trading on Tuesday, hitting $5.49. The company had a trading volume of 1,144,130 shares, compared to its average volume of 1,373,073. The company has a current ratio of 5.43, a quick ratio of 5.03 and a debt-to-equity ratio of 1.11. Precigen, Inc. has a 52 week low of $3.36 and a 52 week high of $11.10. The stock's 50 day moving average price is $5.84 and its 200 day moving average price is $6.78. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -9.15 and a beta of 2.32.

Precigen (NASDAQ:PGEN) last announced its earnings results on Monday, August 9th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. Precigen had a negative return on equity of 70.74% and a negative net margin of 107.46%. Analysts predict that Precigen, Inc. will post -0.49 earnings per share for the current year.

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Precigen in a research report on Tuesday, August 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Precigen presently has a consensus rating of "Buy" and a consensus price target of $12.75.

Several institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System raised its holdings in shares of Precigen by 8.0% during the first quarter. Arizona State Retirement System now owns 21,595 shares of the biotechnology company's stock valued at $149,000 after acquiring an additional 1,607 shares in the last quarter. American International Group Inc. raised its holdings in shares of Precigen by 5.9% during the first quarter. American International Group Inc. now owns 40,784 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 2,285 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Precigen by 5.6% during the second quarter. Legal & General Group Plc now owns 45,546 shares of the biotechnology company's stock valued at $297,000 after acquiring an additional 2,399 shares in the last quarter. Bridgefront Capital LLC raised its holdings in shares of Precigen by 29.1% during the second quarter. Bridgefront Capital LLC now owns 13,729 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 3,097 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Precigen by 10.0% during the second quarter. State Board of Administration of Florida Retirement System now owns 35,247 shares of the biotechnology company's stock valued at $230,000 after acquiring an additional 3,215 shares in the last quarter. Institutional investors own 68.58% of the company's stock.

About Precigen

Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics.

Featured Article: What is a Fiduciary?

Insider Buying and Selling by Quarter for Precigen (NASDAQ:PGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Precigen right now?

Before you consider Precigen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.

While Precigen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.